Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Heidelberg Pharma AG    WL6   DE000A11QVV0

HEIDELBERG PHARMA AG (WL6)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Heidelberg Pharma AG : Notification and public disclosure of transactions by persons

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 04:30pm CEST


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

10.11.2017 / 16:28
The issuer is solely responsible for the content of this announcement.


1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Name and legal form: NewMarket Venture Verwaltungs GmbH

2. Reason for the notification

a) Position / status
Person closely associated with:
Title: Prof. Dr.
First name: Christof
Last name(s): Hettich
Position: Member of the administrative or supervisory body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
Heidelberg Pharma AG

b) LEI
391200E09XYBYITR1W32 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Derivative
ISIN: DE000A2GSZB8

b) Nature of the transaction
Granting of 40,141 subscription rights within a capital increase

c) Price(s) and volume(s)
Price(s) Volume(s)
0 EUR 0 EUR

d) Aggregated information
Price Aggregated volume
0 EUR 0.0000 EUR

e) Date of the transaction
2017-11-09; UTC+1

f) Place of the transaction
Outside a trading venue



10.11.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Internet: www.heidelberg-pharma.com

 
End of News DGAP News Service

38785  10.11.2017 


© EQS 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HEIDELBERG PHARMA AG
04/12HEIDELBERG PHARMA AG : Interim Management Statement on the First Three Months of..
EQ
04/09HEIDELBERG PHARMA : Presents Proprietary ATAC Technology Platform at Two Scienti..
EQ
03/29HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
03/22HEIDELBERG PHARMA AG : Heidelberg Pharma announces financial figures for fiscal ..
EQ
03/19HEIDELBERG PHARMA AG : annual earnings release
03/15HEIDELBERG PHARMA : Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Mu..
AQ
03/05HEIDELBERG PHARMA AG : Heidelberg Pharma and Magenta Therapeutics Sign Exclusive..
EQ
03/05HEIDELBERG PHARMA AG : Heidelberg Pharma and Magenta Therapeutics Sign Exclusive..
EQ
03/01HEIDELBERG PHARMA : Signs License Agreement with The University of Texas MD Ande..
EQ
02/28HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
More news
News from SeekingAlpha
2016Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target 
Financials (€)
Sales 2018 3,97 M
EBIT 2018 -12,9 M
Net income 2018 -13,0 M
Finance 2018 25,1 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 14,7x
EV / Sales 2019 16,5x
Capitalization 83,3 M
Chart HEIDELBERG PHARMA AG
Duration : Period :
Heidelberg Pharma AG Technical Analysis Chart | WL6 | DE000A11QVV0 | 4-Traders
Technical analysis trends HEIDELBERG PHARMA AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,25 €
Spread / Average Target 44%
EPS Revisions
Managers
NameTitle
Jan Schmidt-Brand Chief Executive & Financial Officer
Christof Hettich Chairman-Supervisory Board
Andreas Pahl Head-Research & Development
Friedrich von Bohlen und Halbach Member-Supervisory Board
Georg F. Baur Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HEIDELBERG PHARMA AG-8.90%102
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.75%14 493
NEKTAR THERAPEUTICS44.36%13 873